Tedizolid phosphate and ceftolozane/tazobactam by Cubist Pharmaceutical, ceftazidime/avibactam by AstraZeneca PLC, amikacin inhale by Bayer Healthcare, plazomicin by Achaogen, Inc. and Synflorix by GlaxoSmithKline are the phase III candidates. Considering the antibacterial efficiency, and current market competition, tedizolid phosphate is expected to be the most preferred drug for treatment of nosocomial pneumonia. Amikacin inhale, an aerosolized drug is intended for sale as a drug device combination. Majority of the drugs in the late stages are biological drugs. Aridis Pharmaceutical holds four investigational drugs against various causative agents of hospital acquired pneumonia, each being monoclonal antibody therapy.
Increased Prevalence of the Infection Drives Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market
The global pipeline analysis of hospital acquired pneumonia drugs market is driven by the rising incidences of nosocomial pneumonia or Hospital-acquired pneumonia.
Hospital-acquired pneumonia (HAP) or nosocomial pneumonia is one of the leading reasons for mortality and morbidity despite the existence of improved supportive care, antimicrobial, and prevention therapy.
Hospital-acquired pneumonia or nosocomial pneumonia is any pneumonia that is acquired by a patient in the settings of a hospital at least after 48 to 72 hours of being admitted. It is, as such, is much different from community-acquired pneumonia. Generally, bacterial infection rather than a viral one causes hospital-acquired pneumonia. A patient suffering from hospital-acquired pneumonia usually exhibits a combination of leukocytosis or leucopenia, poor oxygenation, hypothermia or fever, and augmented tracheal secretions.
Request Sample Of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1881
Multidrug Resistance of Hospital-acquired Pneumonia Causing Bacteria Fuels Growth
Nosocomial or hospital acquired pneumonia gives rise to several complications and create complicate the medical condition for patients admitted in hospitals across the globe. Multidrug resistant microorganisms are responsible for the occurrence of these infections. These infections considerably diminish the patient’s ability to recuperate and numerous comorbidities also follow, which is likely to support growth of the global pipeline analysis of hospital acquired pneumonia drugs market in the years to come.
Some of the symptoms of hospital-acquired pneumonia comprise the following
- A cough with pus-like or greenish phlegm (sputum)
- Chills and fever
- Loss of appetite
- Vomiting and nausea
- Sharp pain in the chest pain that gets worse with deep breathing or coughing
- Shortness of breath
- General discomfort, uneasiness, or ill feeling (malaise)
- Fast heart rate and decreased blood pressure and
These organisms, being multidrug resistant, are immune to the usual antibiotics. Multidrug resistance makes it difficult for the conventional antibiotics to treat the infection acquired in the hospital, which is expected to boost the global pipeline analysis of hospital acquired pneumonia drugs market. Pneumonia is considered one of the most prominent infections caused in the premises of a hospital. Incidences of hospital-acquired pneumonia are quite high in the elderly and infant patients, immunocompromised patients. It also attacks patients going through enteral feeding and in post surgical infections.
Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1881
Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of hospital acquired pneumonia are common in immunocompromised patients, post surgical infections, enteral feeding, elderly and infant patients. As hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator air, it is also called as ventilator associated pneumonia. Major causative pathogens include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) has also been found to be a major causative agent of nosocomial pneumonia in new borne.
Currently there are four drugs authorized for treatment of hospital acquired pneumonia; these include Zosyn (piperacillin/tazobactam), Zyvox (linezolid), Tygacil (tigecycline), and Vibativ (telavancin). Consistent research and development is being conducted in view of introducing more effective treatment options. There are five investigational drugs and one vaccine in stage III clinical trials, while ten other candidates in early stage, which mainly include biological drugs.
Request the Coronavirus Impact Analysis across Industries and Markets - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1881
Tedizolid phosphate and ceftolozane/tazobactam by Cubist Pharmaceutical, ceftazidime/avibactam by AstraZeneca PLC, amikacin inhale by Bayer Healthcare, plazomicin by Achaogen, Inc. and Synflorix by GlaxoSmithKline are the phase III candidates. Considering the antibacterial efficiency, and current market competition, tedizolid phosphate is expected to be the most preferred drug for treatment of nosocomial pneumonia. Amikacin inhale, an aerosolized drug is intended for sale as a drug device combination. Majority of the drugs in the late stages are biological drugs. Aridis Pharmaceutical holds four investigational drugs against various causative agents of hospital acquired pneumonia, each being monoclonal antibody therapy.
71065